Evidence map›Paper›PMID 19364473›Full record

ReviewBiochimica et biophysica acta2009

Integrative genomic approaches to understanding cancer.

William C Hahn, Ian F Dunn, So Young Kim, Anna C Schinzel, Ron Firestein, Isil Guney, Jesse S Boehm

Abstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

William C HahnCenter for Cancer Genome Discovery, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA. william_hahn@dfci.harvard.edu
Ian F Dunn
So Young Kim
Anna C Schinzel
Ron Firestein
Isil Guney
Jesse S Boehm

Funding

Signatures of Kinase Activation in Cancer (MIT consortium)U54CA112962 · NCI · DANA-FARBER CANCER INSTITUTE · PI GOLUB, TODD R. · 2004 to 2014
$24.2M
Transgenic Mouse and Biobank CoreP01CA095616 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2003 to 2012
$20.3M
Integrated genomic approaches to identify and validate cancer targetsR33CA128625 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2008 to 2010
$1.6M
NCI NIH HHS P01 CA095616NCI NIH HHS R33 CA128625NCI NIH HHS U54 CA112962
6 · The paper itself

Abstract

Further advances in the prevention, diagnosis and treatment of cancer require a more complete knowledge of the molecular mechanisms that program the malignant state. Until recently, identifying and validating genetic alterations in tumors that contribute to cancer involved painstaking efforts focused primarily on single mutations. However, the application of whole genome approaches to the study of cancer now makes it possible to contemplate performing systematic characterizations of the structural basis of cancer by identifying mutations associated with each cancer type. In parallel, recent technological advances also make it possible to methodically characterize the function of putative oncogenes and tumor suppressor genes. The integration of these approaches now provides the means to not only derive a complete molecular description of cancer but will also provide well-validated targets for the development of therapeutic agents.

Indexed as

Genome, HumanGene DosageGenomicsHumansMutationNeoplasmsTranslocation, Genetic

Identifiers

PMID19364473
PMCPMC2692376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.